Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam

• Main Authors: Bassetti M, Peghin M, Mesini A, Castagnola E
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-06-01
• Series: Infection and Drug Resistance
• Subjects: pediatric; infections; multidrug-resistant gram-negative; ceftazidime/avibactam
• Online Access: https://www.dovepress.com/optimal-management-of-complicated-infections-in-the-pediatric-patient--peer-reviewed-article-IDR
• ISSN: 1178-6973

Matteo Bassetti,1,2 Maddalena Peghin,1 Alessio Mesini,3 Elio Castagnola3 1Infectious Diseases Clinic, Department of Medicine University of Udine and Azienda Sanitaria Universitaria Integrata, Udine, Italy; 2Department of Health Sciences, University of Genoa, Genoa, Italy; 3Division of Infectious Diseases, IRCCS Istituto Giannina Gaslini, Genoa, ItalyCorrespondence: Matteo BassettiClinica Malattie Infettive, Azienda Ospedaliera Universitaria Santa Maria Della Misericordia, Piazzale Santa Maria Della Misericordia 15, Udine 33100, ItalyTel [phone]Fax [phone]Email [e-mail]: Antimicrobial resistance poses a substantial threat to global public health. The pursuit of new antibiotics has decreased and very few options have been investigated for the treatment of complicated multidrug-resistant Gram-negative (MDR-GN) infections in adult population and even less in pediatric patients. Ceftazidime-avibactam (CAZ-AVI) is novel cephalosporin/β-lactamase inhibitor (BL-BLI) combination with broad antibacterial spectrum. The aim of this review is to describe the current and future role CAZ-AVI in the pediatric population with suspected or confirmed MDR-GN infections.Keywords: pediatric, infections, multidrug-resistant Gram-negative, ceftazidime/avibactam